GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026

GT Biopharma, Inc. (NASDAQ: GTBP), a clinical-stage immuno-oncology firm, is set to host a live company presentation today, September 11, 2026, focusing on its proprietary TriKE® platform, aimed at revolutionizing cancer treatment. The presentation will commence at 2:00 PM Eastern Time and features insights from Michael Breen, the Executive Chairman and CEO, alongside Dr. Jeffrey Miller, Consulting Senior Medical Director. They are expected to discuss the latest clinical advancements in treating blood cancers and solid tumors, delve into results from increasing dose levels, explore the TriKE® platform's competitive positioning, and outline significant upcoming milestones.

The TriKE® platform is designed to harness and amplify the natural killing abilities of patients' immune system natural killer (NK) cells, aiming to enhance cancer cell destruction. This innovation stems from an exclusive worldwide licensing agreement with the University of Minnesota, which empowers GT Biopharma to further develop and commercialize NK cell therapies utilizing this groundbreaking technology.

Investors and stakeholders are encouraged to participate in the webcast to gain insights into the company’s clinical progress and the feasibility of NK cell immunotherapy in contemporary cancer treatment paradigms. A replay of the presentation will be available on the company’s website following the event.

As a matter of caution, the company highlights that certain statements made during the presentation may be considered forward-looking, potentially influenced by various risks and uncertainties. Thus, actual results could differ substantially from current expectations. For further insights and developments, stakeholders can refer to GT Biopharma’s filings with the Securities and Exchange Commission.

For additional information, please visit the company’s official website at gtbiopharma.com.

As GT Biopharma, Inc. (NASDAQ: GTBP) prepares to host a live presentation on September 11, 2026, focused on its proprietary TriKE® platform for cancer treatment, investors should closely monitor the session for insights into the advancement of clinical trials and strategic positioning. The presentation, featuring key figures such as CEO Michael Breen and Dr. Jeffrey Miller, promises to shed light on the platform's efficacy against blood cancers and solid tumors, a critical factor that could influence stock performance.

The TriKE® (T Cell Engager) platform leverages natural killer (NK) cells, enhancing their ability to target and eliminate cancer cells. Given the increasing demand for innovative cancer therapies in the lucrative immuno-oncology market, GT Biopharma’s focus on this technology could be pivotal. Investors should be aware of how the company articulates its current clinical achievements and the competitive landscape, especially as they introduce new data around escalating dose levels and clinical milestones.

In addition to the technological insights, it's important to consider the broader market context. The immuno-oncology sector has experienced tremendous growth, and positive updates from GT Biopharma could attract interest from institutional investors aimed at capitalizing on cutting-edge treatments. However, investors must remain vigilant of the inherent volatility in clinical-stage companies. The forward-looking statements in the release underscore the uncertainty surrounding trial results and regulatory approvals.

In light of these factors, investors may find the live presentation a crucial opportunity to gauge GT Biopharma’s trajectory. A well-received presentation could lead to a short-term uptick in share prices, while any cautious messaging might prompt a reevaluation of investment positions. Thus, it's advisable to participate in the webinar or review the recorded session for detailed insights that could inform future trading strategies.